Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression

•DKI may help noninvasively differentiate glioma recurrence from pseudoprogression.•DKI and DSC may have a complementary predictive value for the discrimination.•The combination of DKI and DSC improves the differential diagnostic performance. To compare the added value of diffusion kurtosis imaging...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of radiology 2021-11, Vol.144, p.109941-109941, Article 109941
Hauptverfasser: Shi, Wenwei, Qu, Chongxiao, Wang, Xiaochun, Liang, Xiao, Tan, Yan, Zhang, Hui
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•DKI may help noninvasively differentiate glioma recurrence from pseudoprogression.•DKI and DSC may have a complementary predictive value for the discrimination.•The combination of DKI and DSC improves the differential diagnostic performance. To compare the added value of diffusion kurtosis imaging (DKI) with the combination of dynamic susceptibility contrast-enhanced (DSC) MRI in differentiating glioma recurrence from pseudoprogression. Thirty-four patients with high-grade gliomas developing new and/or increasing enhanced lesions within six months after surgery and chemoradiotherapy were retrospectively analyzed. All patients were pathologically confirmed to have recurrent glioma (n = 22) or pseudoprogression (n = 12). The DKI and DSC MRI parameters were calculated based on the enhanced lesions on contrast-enhanced T1WI. ROC analysis was performed on significant variables to determine their diagnostic performance. Multivariate logistic regression was used to determine the best prediction model for discrimination. The relative mean kurtosis (rMK), relative axial kurtosis (rKa), relative cerebral blood volume (rCBV), and relative mean transit time (rMTT) of glioma recurrence were higher than those of pseudoprogression (all, P 
ISSN:0720-048X
1872-7727
DOI:10.1016/j.ejrad.2021.109941